New drug combo aims to keep blood cancer at bay after transplant
NCT ID NCT02253316
Summary
This study is testing a three-drug treatment called IRD given after a patient's own stem cell transplant for multiple myeloma. The goal is to help patients stay disease-free for a longer time after their transplant. After the initial treatment, patients receive ongoing 'maintenance' therapy with one of the drugs to try to prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
Washington University School of Medicine
St Louis, Missouri, 62864, United States
Conditions
Explore the condition pages connected to this study.